| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. | J Mol Biol | 2007 | 2.45 |
| 2 | Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. | J Mol Biol | 2005 | 1.80 |
| 3 | B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. | J Pharmacol Exp Ther | 2010 | 1.09 |
| 4 | Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. | J Virol | 2006 | 1.09 |